Europe Molecular Point of Care Testing (Using NAAT) Market – Industry Trends and Forecast to 2028

  • Medical Devices
  • Published Report
  • Dec 2021
  • Europe
  • 350 Pages
  • No of Tables: 305
  • No of Figures: 42

Europe Molecular Point of Care Testing (Using NAAT), By Product (Instruments And Consumables And Reagents), Indication (Respiratory Infections Testing, Sexually Transmitted Infection (STI) Testing, Gastrointestinal Tract Infections Testing And Others), End User ( Laboratories, Hospitals, Clinics, Home Care, Ambulatory Centers, Assisted Living Facilities And Others), Mode Of Testing ( Prescription-Based Testing And OTC-Based Testing), Distribution Channel (Direct Sales, Third Party Distributors, Online Sales), Country (Germany, France, U.K., Italy, Spain and Rest of Europe), Industry Trends and Forecast to 2028

Europe Molecular Point of Care Testing (Using NAAT) Market Market Analysis and Insights: Europe Molecular Point of Care Testing (Using NAAT) Market 

Europe molecular point of care testing (using NAAT) market is expected to reach USD 13,542.73 million by 2028, from USD 5,764.26 million in 2020, growing at the CAGR of 10.0% in the forecast period of 2021 to 2028.

POCT is characterized as testing which can be done close to the patient where a medical decision can be made immediately, including the results and monitoring. POCT devices now entering into clinical use are based on nucleic acid amplification technologies (NAAT), defined here as second-generation devices. These platforms generally have improved sensitivity, typically in the range of 60 to 90%, compared to first-generation POCTs, and require portable instrumentation with a footprint of approximately 30cm x 30cm. These instruments are essentially used in the molecular detection of various disorders such as HIV, HPV, and respiratory disease through NAAT technology. NAAT is Nucleic Acid Amplification Techniques which allows identification of pathogenic organisms by detecting their DNA or RNA.

In the global pandemic, attempt to synergize the sensitivity of NAATs and the ease of use of POCT assays, miniaturized NAAT-based POCT devices and assays were devised for faster screening and diagnosis of COVID-19, which also propelled the growth of the market.

Molecular point-of-care testing's significant advantages include the rapid diagnosis process, treatment choice, monitoring, and prognosis. This will also help in operational decision-making and proper resource utilization. The increasing prevalence of chronic disease and increasing diagnosis-seeking rate are expected to act as drivers for the market. However, the high cost of POCT instruments may hinder the growth of the market.

The strategic initiatives taken by the major players are anticipated to provide lucrative opportunities for the market's growth. On the other hand, the stringent regulatory approval may act as a challenge for the market

This Europe molecular point of care testing (using NAAT) market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an Analyst Brief. Our team will help you create a revenue impact solution to achieve your desired goal.

Europe Molecular Point of Care Testing (Using NAAT) Market Europe Molecular Point of Care Testing (Using NAAT) market scope and market size

Europe Molecular Point of Care Testing (Using NAAT) market is segmented into five notable segments which are based on the product, indication, end user, mode of testing, and distribution channel.

  • On the basis of product, the Europe molecular point of care testing (using NAAT) market is segmented into instruments, consumables, and reagents. In 2021, the consumables & reagents segment in the molecular point of care testing (using NAAT) market is expected to grow due to the growing demand for molecular testing of disease in a minimum time frame.
  • On the basis of indication, the Europe molecular point of care testing (using NAAT) market is segmented into sexually transmitted infection (STI) testing, respiratory infection testing, gastrointestinal tract infection testing, and others. In 2021, the respiratory segment in the molecular point of care testing (using NAAT) market is expected to dominate because of a sudden outbreak of COVID-19 and a rise in the incidence of various other respiratory disorders due to the no-contact spread of the disease.
  • On the basis of end user, the Europe molecular point of care testing (using NAAT) market is segmented into laboratories, hospitals, clinics, ambulatory centers, home care, assisted living facilities, and others. In 2021, the laboratories segment in the molecular point of care testing (using NAAT) market is expected to dominate as the European countries have an excellent medical infrastructure, and most of the laboratories in these regions are NAB accredited.
  • On the basis of the mode of testing, the Europe molecular point of care testing (using NAAT) market is segmented into prescription-based testing and OTC testing. In 2021, the prescription-based testing segment in the molecular point of care testing (using NAAT) market is expected to grow due to the fact that the molecular NAAT is the testing of DNA and RNA, which is to be performed under medical supervision, which increases the market share for prescription-based testing.
  • On the basis of distribution channel, the Europe molecular point of care testing (using NAAT) market is segmented into direct tender, third party distributor, online sales. In 2021, the direct sales segment in the molecular point of care testing (using NAAT) market is expected to grow due to the excellent healthcare in European countries, due to which the procurement of these products will be done on a regular basis.

Europe Molecular Point of Care Testing (Using NAAT) Market Country Level Analysis

The Europe molecular point of care testing (Using NAAT) market is analyzed, and market size information is provided by the product, by indication, by mode of testing, end user, by distribution channel.

U.K. is expected to dominate the market because of the increasing diagnosis rate and awareness about chronic disease. 

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data. 

Strategic Initiative Taken By Market Players is Creating New Opportunities For Players in The Molecular Point Of Care Testing (Using NAAT) Market

Europe molecular point of care testing (using NAAT) market also provides you with detailed market analysis for every country growth in aesthetic industry with Europe molecular point of care testing (using NAAT) market sales, impact of advancement in the Europe molecular point of care testing (using NAAT) market and changes in regulatory scenarios with their support for the Europe molecular point of care testing (using NAAT) market. The data is available for the historic period 2010 to 2018. 

Competitive Landscape and Molecular Point of Care Testing (Using NAAT) Market Share Analysis

Europe molecular point of care testing (using NAAT) market competitive landscape provides details by a competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company's focus related to molecular point of care testing (using NAAT) market.

The major companies providing Molecular Point of Care Testing (Using NAAT) products in Europe molecular point of care testing (Using NAAT) market are Danaher, Thermo Fisher Scientific Inc., Hologic, Inc., BD, F. Hoffmann-La Roche Ltd, ABBOTT, Seegene Inc., bioMérieux SA, QIAGEN, Bio-Rad Laboratories, Inc., PerkinElmer Inc., Grifols, S.A., Quidel Corporation, GenMark Diagnostics, Inc., SD Biosensor, INC., Oxford Nanopore Technologies, Wondfo, Randox Laboratories Ltd., Meridian Bioscience, Sekisui Diagnostics, QuantuMDx Group Ltd., Lucira Health Inc., binx health, inc., among others.

Many product launches and agreements are also initiated by the companies worldwide, which are also accelerating the Europe molecular point of care testing (using NAAT) market.

For instance, 

  • In November 2021, Co-Diagnostics, Inc. announced that they are going to host the booth this week at the MEDICA 2021 trade fair in Düsseldorf, Germany. This will be added as an achievement and will contribute to the future business expansion in the forecast period
  • In November, Co-Diagnostics, Inc. announced that their product Logix COVID-19 testing instrument was being approved in U.K. This has led to increased demand from the European region and will contribute to the revenue of the company

This new product launched by the company has increased its protein estimation portfolio in the market. Collaboration, joint ventures, and other strategies by the market player is enhancing the company market in the Molecular Point of Care Testing (Using NAAT) market, which also provides the benefit for the organization to improve their offering for Molecular point of care testing (using NAAT) market.

Customization Available: Europe Molecular Point of Care Testing (Using NAAT) Market 

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market, and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

TABLE 1 CEPHEID: ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)

TABLE 2 THERMO FISHER SCIENTIFIC INC. : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)

TABLE 3 HOLOGIC, INC. : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)

TABLE 4 BD : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)

TABLE 5 F. HOFFMANN-LA ROCHE LTD : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)

TABLE 6 NUMBER OF POCT INSTRUMENTS INSTALLED IN EACH COUNTRY, 2020 (UNITS)

TABLE 7 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS NORTH AMERICA (USD)

TABLE 8 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS NORTH AMERICA (USD)

TABLE 9 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS NORTH AMERICA (USD)

TABLE 10 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS NORTH AMERICA (USD)

TABLE 11 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS NORTH AMERICA (USD)

TABLE 12 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS NORTH AMERICA (USD)

TABLE 13 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS EUROPE (USD)

TABLE 14 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS EUROPE (USD)

TABLE 15 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS EUROPE (USD)

TABLE 16 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS EUROPE (USD)

TABLE 17 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS EUROPE (USD)

TABLE 18 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS EUROPE (USD)

TABLE 19 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS SOUTH ASIA (USD)

TABLE 20 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS SOUTH ASIA (USD)

TABLE 21 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS SOUTH ASIA (USD)

TABLE 22 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS SOUTH ASIA (USD)

TABLE 23 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS SOUTH ASIA (USD)

TABLE 24 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS SOUTH ASIA (USD)

TABLE 25 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS SOUTH EAST ASIA (USD)

TABLE 26 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS SOUTH EAST ASIA (USD)

TABLE 27 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS SOUTH EAST ASIA (USD)

TABLE 28 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS SOUTH EAST ASIA (USD)

TABLE 29 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS SOUTH EAST ASIA (USD)

TABLE 30 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS SOUTH EAST ASIA (USD)

TABLE 31 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS MIDDLE EAST (USD)

TABLE 32 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS MIDDLE EAST (USD)

TABLE 33 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS MIDDLE EAST (USD)

TABLE 34 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS MIDDLE EAST (USD)

TABLE 35 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS MIDDLE EAST (USD)

TABLE 36 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS MIDDLE EAST (USD)

TABLE 37 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS AFRICA (USD)

TABLE 38 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS AFRICA (USD)

TABLE 39 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS AFRICA (USD)

TABLE 40 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS AFRICA (USD)

TABLE 41 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS AFRICA (USD)

TABLE 42 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS AFRICA (USD)

TABLE 43 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS NORTH AMERICA (USD)

TABLE 44 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS NORTH AMERICA (USD)

TABLE 45 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS NORTH AMERICA (USD)

TABLE 46 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS NORTH AMERICA (USD)

TABLE 47 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS NORTH AMERICA (USD)

TABLE 48 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS NORTH AMERICA (USD)

TABLE 49 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS NORTH AMERICA (USD)

TABLE 50 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS NORTH AMERICA (USD)

TABLE 51 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS NORTH AMERICA (USD)

TABLE 52 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS NORTH AMERICA (USD)

TABLE 53 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS NORTH AMERICA (USD)

TABLE 54 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS NORTH AMERICA (USD)

TABLE 55 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS NORTH AMERICA (USD)

TABLE 56 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS NORTH AMERICA (USD)

TABLE 57 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS NORTH AMERICA (USD)

TABLE 58 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS NORTH AMERICA (USD)

TABLE 59 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS NORTH AMERICA (USD)

TABLE 60 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS NORTH AMERICA (USD)

TABLE 61 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS NORTH AMERICA (USD)

TABLE 62 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS NORTH AMERICA (USD)

TABLE 63 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS NORTH AMERICA (USD)

TABLE 64 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS NORTH AMERICA (USD)

TABLE 65 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS NORTH AMERICA (USD)

TABLE 66 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS NORTH AMERICA (USD)

TABLE 67 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS EUROPE (USD)

TABLE 68 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS EUROPE (USD)

TABLE 69 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS EUROPE (USD)

TABLE 70 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS EUROPE (USD)

TABLE 71 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS EUROPE (USD)

TABLE 72 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS EUROPE (USD)

TABLE 73 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS EUROPE (USD)

TABLE 74 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS EUROPE (USD)

TABLE 75 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS EUROPE (USD)

TABLE 76 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS EUROPE (USD)

TABLE 77 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS EUROPE (USD)

TABLE 78 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS EUROPE (USD)

TABLE 79 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS EUROPE (USD)

TABLE 80 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS EUROPE (USD)

TABLE 81 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS EUROPE (USD)

TABLE 82 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS EUROPE (USD)

TABLE 83 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS EUROPE (USD)

TABLE 84 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS EUROPE (USD)

TABLE 85 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS EUROPE (USD)

TABLE 86 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS EUROPE (USD)

TABLE 87 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS EUROPE (USD)

TABLE 88 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS EUROPE (USD)

TABLE 89 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS EUROPE (USD)

TABLE 90 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS EUROPE (USD)

TABLE 91 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH ASIA (USD)

TABLE 92 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH ASIA (USD)

TABLE 93 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH ASIA (USD)

TABLE 94 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH ASIA (USD)

TABLE 95 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH ASIA (USD)

TABLE 96 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH ASIA (USD)

TABLE 97 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH ASIA (USD)

TABLE 98 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH ASIA (USD)

TABLE 99 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH ASIA (USD)

TABLE 100 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH ASIA (USD)

TABLE 101 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH ASIA (USD)

TABLE 102 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH ASIA (USD)

TABLE 103 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH ASIA (USD)

TABLE 104 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH ASIA (USD)

TABLE 105 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH ASIA (USD)

TABLE 106 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH ASIA (USD)

TABLE 107 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH ASIA (USD)

TABLE 108 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH ASIA (USD)

TABLE 109 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH ASIA (USD)

TABLE 110 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH ASIA (USD)

TABLE 111 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH ASIA (USD)

TABLE 112 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH ASIA (USD)

TABLE 113 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH ASIA (USD)

TABLE 114 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH ASIA (USD)

TABLE 115 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 116 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 117 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 118 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 119 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 120 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 121 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 122 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 123 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 124 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 125 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 126 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 127 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 128 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 129 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 130 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 131 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 132 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 133 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 134 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 135 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 136 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 137 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 138 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 139 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS MIDDLE EAST (USD)

TABLE 140 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS MIDDLE EAST (USD)

TABLE 141 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS MIDDLE EAST (USD)

TABLE 142 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS MIDDLE EAST (USD)

TABLE 143 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS MIDDLE EAST (USD)

TABLE 144 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS MIDDLE EAST (USD)

TABLE 145 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS MIDDLE EAST (USD)

TABLE 146 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS MIDDLE EAST (USD)

TABLE 147 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS MIDDLE EAST (USD)

TABLE 148 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS MIDDLE EAST (USD)

TABLE 149 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS MIDDLE EAST (USD)

TABLE 150 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS MIDDLE EAST (USD)

TABLE 151 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS MIDDLE EAST (USD)

TABLE 152 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS MIDDLE EAST (USD)

TABLE 153 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS MIDDLE EAST (USD)

TABLE 154 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS MIDDLE EAST (USD)

TABLE 155 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS MIDDLE EAST (USD)

TABLE 156 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS MIDDLE EAST (USD)

TABLE 157 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS MIDDLE EAST (USD)

TABLE 158 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS MIDDLE EAST (USD)

TABLE 159 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS MIDDLE EAST (USD)

TABLE 160 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS MIDDLE EAST (USD)

TABLE 161 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS MIDDLE EAST (USD)

TABLE 162 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS MIDDLE EAST (USD)

TABLE 163 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS AFRICA (USD)

TABLE 164 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS AFRICA (USD)

TABLE 165 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS AFRICA (USD)

TABLE 166 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS AFRICA (USD)

TABLE 167 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS AFRICA (USD)

TABLE 168 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS AFRICA (USD)

TABLE 169 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS AFRICA (USD)

TABLE 170 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS AFRICA (USD)

TABLE 171 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS AFRICA (USD)

TABLE 172 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS AFRICA (USD)

TABLE 173 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS AFRICA (USD)

TABLE 174 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS AFRICA (USD)

TABLE 175 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS AFRICA (USD)

TABLE 176 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS AFRICA (USD)

TABLE 177 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS AFRICA (USD)

TABLE 178 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS AFRICA (USD)

TABLE 179 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS AFRICA (USD)

TABLE 180 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS AFRICA (USD)

TABLE 181 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS AFRICA (USD)

TABLE 182 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS AFRICA (USD)

TABLE 183 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS AFRICA (USD)

TABLE 184 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS AFRICA (USD)

TABLE 185 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS AFRICA (USD)

TABLE 186 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS AFRICA (USD)

TABLE 187 NORTH AMERICA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 188 NORTH AMERICA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 189 EUROPE MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 190 EUROPE MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 191 SOUTH ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 192 SOUTH ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 193 SOUTH EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 194 SOUTH EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 195 MIDDLE EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 196 MIDDLE EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 197 AFRICA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 198 AFRICA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 199 NORTH AMERICA MARKET SHARE ANALYSIS BY COMPANIES FOR SEXUALLY TRANSMITTED INFECTIONS (STI) IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 200 EUROPE MARKET SHARE ANALYSIS BY COMPANIES FOR SEXUALLY TRANSMITTED INFECTIONS (STI) IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 201 SOUTH ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR SEXUALLY TRANSMITTED INFECTIONS (STI) IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 202 SOUTH EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR SEXUALLY TRANSMITTED INFECTIONS (STI) IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 203 MIDDLE EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR SEXUALLY TRANSMITTED INFECTIONS (STI) IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 204 AFRICA MARKET SHARE ANALYSIS BY COMPANIES FOR SEXUALLY TRANSMITTED INFECTIONS (STI) IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 205 NORTH AMERICA MARKET SHARE ANALYSIS BY COMPANIES FOR GASTROINTESTINAL INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 206 EUROPE MARKET SHARE ANALYSIS BY COMPANIES FOR GASTROINTESTINAL INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 207 SOUTH ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR GASTROINTESTINAL INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 208 SOUTH EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR GASTROINTESTINAL INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 209 MIDDLE EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR GASTROINTESTINAL INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 210 AFRICA MARKET SHARE ANALYSIS BY COMPANIES FOR GASTROINTESTINAL INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 211 NORTH AMERICA MARKET SHARE ANALYSIS BY COMPANIES FOR OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 212 EUROPE MARKET SHARE ANALYSIS BY COMPANIES FOR OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 213 SOUTH ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 214 SOUTH EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 215 MIDDLE EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 216 AFRICA MARKET SHARE ANALYSIS BY COMPANIES FOR OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 217 DISTRIBUTORS ACROSS NORTH AMERICA

TABLE 218 DISTRIBUTORS ACROSS EUROPE

TABLE 219 DISTRIBUTORS ACROSS SOUTH ASIA

TABLE 220 DISTRIBUTORS ACROSS SOUTH EAST ASIA

TABLE 221 DISTRIBUTORS ACROSS MIDDLE EAST

TABLE 222 DISTRIBUTORS ACROSS AFRICA

TABLE 223 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 224 EUROPE CONSUMABLES & REAGENTS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 225 EUROPE PEDIATRIC IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 226 EUROPE INSTRUMENTS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 227 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 228 EUROPE RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 229 EUROPE RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 230 EUROPE SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 231 EUROPE SEXUALLY TRANSMITTED IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 232 EUROPE GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 233 EUROPE RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 234 EUROPE OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 235 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 236 EUROPE LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 237 EUROPE HOSPITAL IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 238 EUROPE CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 239 EUROPE AMBULATORY CENTER IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 240 EUROPE HOME CARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 241 EUROPE ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 242 EUROPE ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 243 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 244 EUROPE PRESCRIPTION-BASED TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 245 EUROPE OTC TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 246 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 247 EUROPE DIRECT SALES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 248 EUROPE THIRD PARTY DISTRIBUTOR IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 249 EUROPE ONLINE SALE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 250 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 251 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 252 EUROPE INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 253 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 254 EUROPE RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 255 EUROPE SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 256 EUROPE GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 257 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 258 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 259 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 260 U.K. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 261 U.K. INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 262 U.K. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 263 U.K. RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 264 U.K. SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 265 U.K. GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 266 U.K. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 267 U.K. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 268 U.K. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 269 GERMANY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 270 GERMANY INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 271 GERMANY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 272 GERMANY RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 273 GERMANY SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 274 GERMANY GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 275 GERMANY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 276 GERMANY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 277 GERMANY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 278 ITALY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 279 ITALY INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 280 ITALY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 281 ITALY RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 282 ITALY SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 283 ITALY GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 284 ITALY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 285 ITALY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 286 ITALY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 287 FRANCE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 288 FRANCE INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 289 FRANCE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 290 FRANCE RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 291 FRANCE SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 292 FRANCE GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 293 FRANCE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 294 FRANCE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 295 FRANCE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 296 SPAIN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 297 SPAIN INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 298 SPAIN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 299 SPAIN RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 300 SPAIN SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 301 SPAIN GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 302 SPAIN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 303 SPAIN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 304 SPAIN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 305 REST OF EUROPE & AFRCIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions